Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P339. Epidemiological study of inflammatory bowel disease in single tertiary centre – First report from Serbia

V. Gligorijevic, D. Bojic, M. Nedeljkovic-Protic, P. Svorcan, B. Maksimovic, S. Markovic, N. Jojić

“Zvezdara” University Clinical Center, Gastroenterology and Hepatology Department, Belgrade, Serbia

Background: The papers from last decade show higher incidence rates of inflammatory bowel disease (IBD) in southern and eastern European countries, almost approaching the rates in industrialized countries.

Aims and Methods: This is a prospective epidemiological study of ulcerative colitis (UC) and Crohn's disease (CD) in a single tertiary Zvezdara University Clinical Centre, Belgrade, Serbia. Patients with established diagnosis of UC and CD treated in our Centre from 2000–2010, were included in the study. Demographic data, disease location, ongoing treatment and smoking status were analysed. CARD 15 mutations were determined in CD patients.

Results: A total of 982 IBD patients (49% CD and 51% UC) were included in the study during 10 years follow-up. 51% CD and 67% UC were out-patients. Female/male ratio was 1:1. Median age at diagnosis was 28±1 in CD, and 36±2.3 in UC. There were 67% smokers in CD group and 46% in UC group, while 10% were former smokers in each group. In CD group 74/477 (15%) had ileitis, 21% ileocolitis, 60% colitis and 4% uper GI involvement. Fistulizing disease was found in 22% of CD patients. 37% had one surgical resection, 11% two and 7% three or more. Extraintestinal manifestations had 28% of all patients. At least one CARD 15 mutation was found in 35% of CD patients. In UC group 82% had extensive colitis, 15% left-sided and 3% proctitis. Colectomy was performed in 11% of UC patients. In CD and UC group 32% and 48% of patients were on steroid treatment, 38% and 68% on mesalazine/sulfasalazyne, 40% and 36% on azathyoprine, 10% and 0% on metotrexate and 25% and 16% on infliximab, respectively.

Conclusion: This is the first IBD epidemiological report from Serbia. Real incidence and prevalence rates for IBD patients in Serbia are awaited till the end of ongoing national epidemiological study.